VC
CLBT icon

Voss Capital’s Cellebrite CLBT Stock Holding History

Voss Capital’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76M Buy
+200,000
New +$3.01M 0.15% 42

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Voss Capital's CLBT Position: Q1 2026 in Review

Voss Capital increased its Cellebrite (CLBT) stake by 20% in Q1 2026, buying an estimated $24.5M and bringing the position to 9,675,000 shares worth $133M. The position accounts for 7.07% of the portfolio, ranked #2.

Voss Capital first reported a position in CLBT in Q2 2023 and has held it in 12 quarters since. The position peaked at $145M in Q4 2025. 220 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • Voss Capital held 9,675,000 shares of Cellebrite worth $133M as of Q1 2026.
  • Voss Capital bought 1,625,000 Cellebrite shares in Q1 2026, an estimated $24.5M.
  • Cellebrite made up 7.07% of Voss Capital's portfolio in Q1 2026, its #2 holding.
  • Voss Capital first reported a position in Cellebrite in Q2 2023 and has held it in 12 quarters since.
  • Voss Capital's Cellebrite position peaked at $145M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Voss Capital's 13F filing for Q1 2026, filed 15 May 2026.